Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients
Status:
Recruiting
Trial end date:
2027-12-20
Target enrollment:
Participant gender:
Summary
INDICATION: Oligometastatic hormone-sensitive prostate cancer patients. METHODOLOGY: Open
label, double arm, randomized 1:1, multicenter phase III study.
PRIMARY OBJECTIVE: To assess the efficacy of ablative radiotherapy (SBRT applied to all
oligometastases) administered to all gross tumor sites (metastases and prostate if
applicable), in oligometastatic hormone-sensitive prostate cancer patients.